# Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.

> **NCT04271306** · PHASE1 · TERMINATED · sponsor: **University of Oxford** · enrollment: 34 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** Pfs25-IMX313 (10ug)/Matrix-M (50ug)
- **BIOLOGICAL:** Pfs25-IMX313 (50ug)/Matrix-M (50ug)
- **BIOLOGICAL:** Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)

## Key facts

- **NCT ID:** NCT04271306
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-25
- **Primary completion:** 2024-02-19
- **Final completion:** 2024-02-19
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Due to significant delays in receiving local regulatory approval to extend the shelf-life of the IMP.
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271306, "Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04271306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*